ARWR Earnings

ARWR reported its earnings on 2026-02-05, showcasing a revenue of 264.03M against an estimate of 336.17M, resulting in a -21.46% surprise. The EPS was 0.22, surpassing the expected 0.6 by -63.33%. The stock experienced a -0.19% price change on the earnings day and a -4.78% change over the next five days, reflecting market reactions to the results.

Following ARWR's earnings announcement on 2026-02-05, the stock price moved by -0.19% on the day of the release. Over the subsequent five days, it saw a -4.78% change. Historically, ARWR's stock price tends to shift by an average of -0.35% in the 10 days leading up to earnings and 6.56% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate ARWR's annual revenue to reach 58.94M, while the EPS is projected at -1.08. These estimates reflect recent revisions, with revenue estimates revised upward by 3.68% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ARWR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were revised upward by 3.68%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ARWR's stock price typically moves by -0.35% in the 10 days before its earnings and 6.56% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -1.08 and revenue of 58.94M.

The earnings call reveals strong financial performance, with a significant increase in net income and revenue driven by collaboration agreements. Product development updates, including the commercial launch of REDEMPLO and partnerships with Novartis and Sarepta, are promising. However, management's avoidance of specific questions in the Q&A might cause slight concern. The market cap suggests moderate volatility, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.